Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate

Cancer

Volumn 107, Issue 7, 2006, Pages 1634-1641

  Meirow, Dror ^a   Rabinovici, Jaron ^a   Katz, Daniela ^b   Or, Reuven ^b   Ben Yehuda, Dina ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Depo medroxyprogesterone acetate; Luteinizing hormone releasing hormone agonist; Severe menorrhagia; Treatment induced thrombocytopenia

Indexed keywords

ANTINEOPLASTIC AGENT; GONADORELIN AGONIST; MEDROXYPROGESTERONE ACETATE; TRIPTORELIN;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CONSULTATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MENORRHAGIA; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTOPENIA; VAGINA BLEEDING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MENORRHAGIA; NEOPLASMS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TRIPTORELIN;

EID: 33749621106     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22199     Document Type: Article

References (31)

1. Shpall EJ. The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant. 1999;23(Suppl 2): S13-S19.
2. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002;62(Suppl 1): 1-15.
3. Godder KT, Henslee-Downey PJ. Colony-stimulating factors in stem cell transplantation: effect on quality of life. J Hematother Stem Cell Res. 2001;10:215-228.
4. Demetri GD. Pharmacologic treatment options in patients with thrombocytopenia. Semin Hematol. 2000;37(2 Suppl 4): 11-18.
5. Clarke K, Basser RL. The role of platelet growth factors in cancer therapy. Stem Cells. 1996;14(Suppl 1):274-280.
6. Brown JR, Demetri GD. Challenges in the development of platelet growth factors: low expectations for low counts. Curr Hematol Rep. 2002;1:110-118.
7. Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet. 2002;359:2145-2152.
8. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001; 7:535-543.
9. Muller J. Impact of cancer therapy on the reproductive axis. Horm Res. 2003;59(Suppl 1):12-20.
10. Irvine GA, Cameron IT. Medical management of dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol. 1999;13:189-202.
11. Hanker J. Gastrointestinal disease and oral contraception. Am J Obstet Gynecol. 1990;163(6 Pt 2):2204-2207.
12. Cowan BD, Morrison JC. Management of abnormal genital bleeding in girls and women. N Engl J Med. 1991;324:1710-1715.
13. Rosenfeld JA. Treatment decisions in the management of menorrhagia. Medscape Womens Health. 1997;2:6.
14. Ghalie R, Porter C, Radwanska E, Fitzsimmons W, Richman C, Kaizer H. Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. Am J Hematol. 1993;42:350-353.
15. Sica S, Salutari P, Di Mario A, et al. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. Am J Hematol. 1996;51:248-249.
16. Lhomme C, Brault P, Bourhis JH, et al. Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study. Leuk Lymphoma. 2001;42:1033-1041.
17. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception. 2003;68:75-87.
18. Kaunitz AM. Injectable long-acting contraceptives. Clin Obstet Gynecol. 2001;44:73-91.
19. Kaunitz AM. Injectable contraception. New and existing options. Obstet Gynecol Clin North Am. 2000;27:741-780.
20. Laros RK Jr. Therapeutic amenorrhea in hematologic disorders. Obstet Gynecol. 1971;38:589-593.
21. Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int J Fertil Womens Med. 1998;43:73-83.
22. Roy SN, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. Drug Safety. 2004;27:75-90.
23. Elder MG. Injectable contraception. Clin Obstet Gynaecol. 1984;11:723-741.
24. Frydman R, Parneix I, Belaisch-Allart J, et al. LHRH agonists in IVF: different methods of utilization and comparison with previous ovulation stimulation treatments. Hum Reprod. 1988;3:559-561.
25. Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, vs LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot Study Group. Mol Urol. 2000;4:275-277.
26. Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol. 2001;165:1585-1589.
27. Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther. 2002;301:95-102.
28. Rogers LR. Cerebrovascular complications in patients with cancer. Semin Neurol. 2004;24:453-460.
29. Heit JA. Cancer and venous thromboembolism: scope of the problem. Cancer Control 2005;12(Suppl 1):5-10.
30. Laufer MR, Townsend NL, Parsons KE, et al. Inducing amenorrhea during bone marrow transplantation. A pilot study of leuprolide acetate. J Reprod Med. 1997;42:537-541.
31. Chiusolo P, Salutari P, Sica S, et al. Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. Bone Marrow Transplant. 1998;21:821-823.